News
Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025. On July 24, 2025, Pfizer Inc. (NYSE:PFE) ...
4d
GlobalData on MSNPfizer and 3SBio conclude licensing deal for SSGJ-707
As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...
Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...
Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...
5d
TipRanks on MSNPfizer completes licensing agreement with 3SBio
China, licensing agreement with 3SBio, granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio’s SSGJ-707, a bispecific antibody targeting PD-1 and VEGF ...
Northeastern Chinese company 3SBio to receive $1.25B, in addition to $100M equity investment, $150M for exclusive rights in ...
HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached approximately ...
3SBio also launched Cipterbin (inetetamab) in 2020 and was covered under the National Reimbursement Drug List, or NRDL, the same year. This is an analog of Roche’s anti-HER2 mAb Herceptin.
3SBio has good financial health. As of 2019, total debt was CNY 2.8 billion, net debt was CNY 700 million, and net debt to equity was a mere 7%. We project 2020 operating cash flow at CNY 1.5 ...
3SBio Inc. Annual stock financials by MarketWatch. View the latest 1530 financial statements, income statements and financial ratios.
3Sbio Inc enters distribution and promotion agreement with two subsidiaries of Eli Lilly By Reuters May 16, 20175:03 AM PDTUpdated May 16, 2017 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results